This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Are Consumer Staples Stocks Lagging Altria Group (MO) This Year?
by Zacks Equity Research
Here is how Altria (MO) and Carlsberg AS (CABGY) have performed compared to their sector so far this year.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Behind Altria's Profit Resilience: The Power of Pricing Strategy
by Ansuiya Mohta
MO leans on pricing power to lift profits, offsetting cigarette volume drops and regulatory headwinds.
How to Find Strong Consumer Staples Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will Altria (MO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Altria (MO) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Altria (MO) closed at $57.75 in the latest trading session, marking a -3.01% move from the prior day.
Why Altria (MO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is What to Know Beyond Why Altria Group, Inc. (MO) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Altria (MO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Philip Morris' Pricing Power Behind Its Profit Strength?
by Swati Prasad
PM's strong pricing and premium product mix fuel profit growth and margin gains in the nicotine category.
Altria Group Gains 21% in 6 Months: How to Play the Stock?
by Swati Prasad
MO is gaining ground with strong Marlboro pricing, smoke-free growth, and solid value, appealing to income-focused investors.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Altria (MO) settling at $60.25, representing a +1.01% change from its previous close.
Philip Morris Gains 21% in 3 Months: How to Play the Stock?
by Swati Prasad
PM is gaining ground with smoke-free products and cost cuts, but regulatory and currency risks call for caution.
MO Strengthens on! Brand: Can it Sustain Momentum in Nicotine Pouches?
by Swati Prasad
Altria gains ground in smoke-free with on! pouches, lifting market share and boosting awareness through bold marketing moves.
PM Grows Smoke-Free Profit Share: Will Margins Keep Expanding?
by Swati Prasad
Philip Morris' smoke-free shift gained momentum in the first quarter of 2025 as high-margin products drove profit growth and strengthened its portfolio mix.
4 Stocks to Boost Your Portfolio as S&P 500 Hits New All-Time High
by Ritujay Ghosh
S&P 500 hits a record high--here are four stocks, namely ADBE, MO, ANET and ATO that could strengthen your 2025 portfolio.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVY
Will Altria's Smoke-Free Bets Deliver Long-Term Revenue Lift?
by Ansuiya Mohta
MO's on! pouches drive oral tobacco growth, but NJOY setbacks test its smoke-free strategy and future revenue outlook.
Philip Morris' Valuation Looks Overstretched: Time to Hit Pause?
by Zacks Equity Research
PM's smoke-free pivot fuels a 50% rally, but its stretched valuation may signal a pause for investors.
MO or PM: Which Tobacco Giant Offers Better Value in 2025?
by Ansuiya Mohta
As PM's smoke-free bets pay off, MO's low multiple and on! momentum may offer sharper value in 2025.
5 Low-Beta Defensive Stocks to Buy Amid Sinking Consumer Confidence
by Ritujay Ghosh
As consumer confidence dips, low-beta defensive picks such as MO, INGR and ATO offer growth potential and steady yields.
Top Sin Stocks for Savvy Investors: Profiting From the Unconventional
by Rajani Lohia
Sin stocks offer defensive growth, with steady demand across alcohol, tobacco and gambling sectors, wherein reputation takes a back seat.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Top 3 Tobacco Stocks to Watch Amid Strong Industry Growth Trends
by Ansuiya Mohta
PM, MO and TPB are riding a wave of RRP innovation and pricing power as the tobacco industry pivots toward smoke-free growth.
Altria Group, Inc. (MO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Altria (MO). This makes it worthwhile to examine what the stock has in store.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.